KRAS inhibitor daraxonrasib nearly doubles survival in advanced pancreatic cancer trial

Revolution Medicines' daraxonrasib, a small-molecule inhibitor targeting oncogenic KRAS mutations, has produced striking results in a Phase 3 clinical trial reported at ASCO 2026 and covered across multiple specialist outlets. The trial enrolled patients with advanced pancreatic ductal adenocarcinoma harbouring KRAS mutations — the genetic driver present in roughly 90% of pancreatic cancers — and compared daraxonrasib against standard-of-care chemotherapy. Investigators reported that daraxonrasib nearly doubled median overall survival and reduced the risk of death by approximately 60%.

KRAS was long considered undruggable owing to the smooth surface of its GTP-binding site and the high intracellular concentrations of GTP. Allosteric inhibitors targeting specific KRAS mutant conformations have changed that picture in recent years; daraxonrasib belongs to this class of RAS(ON) multi-selective inhibitors and targets multiple oncogenic KRAS variants simultaneously, a design feature that may explain its breadth of activity.

Reporting by STAT News notes that patient demand is already outpacing supply ahead of any regulatory approval, and that attention is turning to potential use in other KRAS-driven cancers. The drug has not yet received regulatory authorisation from the FDA or EMA. These results represent trial-stage data; their implications for clinical practice will depend on regulatory review and published peer-reviewed data.

Note: this cluster consolidates multiple news write-ups of the same ASCO 2026 trial presentation. Genetic Current previously covered the initial ASCO announcement on 2026-06-01; the present items add patient-access reporting and post-ASCO analytical commentary that extend the story.